

## **Supplemental Table**

**Supplementary Table 1 Characteristics of the 30 patients proven with MMR/MSS mCRC**

<b>Characteristics</b>	<b>Total (n=30) n %</b>
<b>Age (years)</b>	
≥60	12 (40.0)
<60	18 (60.0)
<b>Sex</b>	
Male	14 (46.7)
Female	16 (53.3)
<b>ECOG PS</b>	
0	6 (20.0)
1	15 (50.0)
≥2	9 (30.0)
<b>Site of the primary tumor</b>	
Left	24 (80.0)
Right	6 (20.0)
<b>Site of metastases</b>	
Lung metastases	11 (36.7)
Liver metastases	18 (60.6)

---

Peritoneal metastasis 6 (20.0)

Multiple metastases 18 (60.0)

**MSI/MMR**

MSS (pMMR) 30 (100.0)

MSI-H (dMMR) 0

**Gene status**

BRAF mutation 0

RAS mutation 7 (23.3)

Wild type 12 (40.0)

Not tested 11 (36.7)

**Lines of treatments** 14 (48.2)

Third lines 14 (46.7)

More than third lines 16 (53.3)

**Previous regorafenib treatment** 19 (63.3)

**Clinical response**

SD 18 (60.0)

PD 12 (40.0)

---